Home/ Stocks/ PBYI

PUMA BIOTECHNOLOGY INC

PBYI XNAS

$8.91 +0.56 (+6.94%) ▲ 15-min delayed

Open

$8.15

High

$9.40

Low

$8.12

Volume

683.3K

Market Cap

$413.30M

About PUMA BIOTECHNOLOGY INC

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 179 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$44.81M	$-3,753,000	$-0.07
FY 2025	$228.37M	$31.11M	$0.62
Q3 2025	$54.48M	$8.84M	$0.18
Q2 2025	$52.44M	$5.86M	$0.12

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for PBYI yet. Check out our latest market news or earnings calendar.

Get PBYI Alerts

Stay ahead with breaking news, price alerts, and expert analysis on PUMA BIOTECHNOLOGY INC.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.